Search
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalIt was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Sodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigationalin May 2023. … [L46302] In some countries, sodium oxybate has been investigated and used in alcohol withdrawal syndrome (AWS) to aid abstinence maintenance in alcohol use disorders.[A251440, A251445]
Egg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
Mixtures: Liposyn II Inj 10%, Liposyn IIGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.
Synonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaCategories: Drugs Used in DiabetesCasimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … on further verification in confirmatory trials.
Categories: Compounds used in a research, industrial, or household settingAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawn[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.
Butenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.
Synonyms: (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine, N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamineGestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620] … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.